Panthera Biopartners (Panthera), a Preston, United Kingdom (UK)-based site management organization, just completed a Series A funding round with Gresham House Ventures. Panthera will use the funds to further build out its network of clinical trial sites across the UK and overseas while adding to its team of clinical trials experts, with experience serving both industry sponsors and patients.
As TrialSite has discussed, in the United States, private equity increasingly circulates around, and invests in the clinical trials ecosystem including site organizations, in some cases funding major acquisition-based roll up and consolidation plays. It would appear that this financing activity is commonplace in the UK as well.
An independent site management office (SMO), Panthera helps industry sponsors (biopharma) and contract research organizations (CROs) find the right patient, for the right trial, at the right time, via the identification, recruitment and retention of patients at its own dedicated research sites.
The SMO maintains sites in Preston, London, Manchester and Glasgow. The company is working on developing site relations in other regions as well.
The team includes Founder, Chairman and Chief Financial Officer, Professor John Lyon, BSc (Hons) MSc PhD FCA PhD FCA FICR FCSI, etc. Mr. Lyon spent years working for one of the world’s largest CORs (Covance).
Now Gresham House Ventures is capitalizing on a comparable trend in the UK as is the case in the United States—site consolidation, rationalization and the emergence of the super-site organization. With turnkey services incorporating feasibility, recruitment and other patient access offerings, not to mention compliance, coordination and other options, Gresham House Ventures will see the use of funds help to open the new clinic in Glasgow not to mention expand existing locations to prepare for the need or demand for high patient volumes in the UK and across Europe.
Private equity-backed Gresham House Ventures is a growth equity house specializing in scaling businesses with business models driven by technology, customer insight or service excellence. The team has made over 100 investments in a decade.
An independent SMO, Panthera helps pharmaceutical and contract research organizations find the right patient, for the right trial, at the right time, through the identification, recruitment and retention of patients at its own dedicated research sites. Composed of industry experts, Panthera has about 20 full time equivalents.
Panthera has deep expertise recruiting patients and managing sites in a number of therapeutic areas such as Cardiac disease, Allergies, Migraine, Osteoarthritis, Osteoporosis, Diabetes and more.
Call to Action: TrialSite keeps track of and monitors trial site organizations, including SMOs worldwide. Sign up for the daily newsletter. Sponsors, if you are conducting trials in the UK, then consider Panthera.